Literature DB >> 11922226

Antimicrobial susceptibility pattern of Enterococcus species from urinary tract infections.

Priya A Miskeen1, Lina Deodhar.   

Abstract

OBJECTIVE: To determine the extent of drug-resistance among Enterococcus species in, in vitro experiments. Test strains were isolated from cases with urinary tract infection. Antimicrobial sensitivity was determined with particular reference to the beta-lactams, glycopeptide and aminoglycoside groups of antibiotics.
METHODS: Studies were carried out on pure cultures of enterococci isolated from urine specimens of 147 patients. Freshly voided, aseptically collected, midstream specimens of urine were cultured by using standard techniques. The identification and speciation of the strains of enterococci were performed by employing a battery of tests. In vitro drug-susceptibility tests of enterococci were performed against the following antibiotics: penicillin, ampicillin, ampi-sulbactum, co-amoxi-clavulanate, ciprofloxacin, vancomycin, teicoplanin, gentamicin and streptomycin, by employing the disk diffusion method. MIC values for penicillin, ampicillin, vancomycin and teicoplanin against enterococci were determined by the agar dilution technique. MIC determinations were further carried out by the E-test method, for the glycopeptide antibiotics. Prevalence of high level resistance to aminoglycoside antibiotics was determined by the agar dilution method.
RESULTS: The most common species isolated was E. faecalis (87.07%), followed by E. faecium (10.88%) and E. durans (2.05%). The magnitude of resistance to both penicillin and ampicillin among the Enterococcus spp. was 23.13%, and that to ciprofloxacin was 55.78%. The three antibiotics: nitrofurantoin, co-amoxi-clavulanate, and ampi-sulbactum, showed resistance of 0.78%, 8.16% and 2.72%, respectively. High-level aminoglycoside resistance among strains of enterococci for streptomycin and gentamicin was found to be 33.84% and 36.92%, respectively. All the strains were susceptible to the glycopeptide antibiotics tested.
CONCLUSION: The emergence of enterococci with alarming rates of resistance concomitantly to penicillins and aminoglycosides highlights the need for a more rational and restricted use of antimicrobials, in order to minimize the selection and spread of such strains. An early detection of these problem pathogens is also important for preventing any treatment failures.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11922226

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  5 in total

1.  Beta-hemolytic, multi-lancefield antigen-agglutinating Enterococcus durans from a pregnant woman, mimicking Streptococcus agalactiae.

Authors:  Vincenzo Savini; Alessia Franco; Giovanni Gherardi; Roberta Marrollo; Angela Valentina Argentieri; Fernanda Pimentel de Araujo; Roberta Amoruso; Antonio Battisti; Paolo Fazii; Edoardo Carretto
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

2.  Community-acquired enterococcal urinary tract infections.

Authors:  Maria Bitsori; Sofia Maraki; Maria Raissaki; Anna Bakantaki; Emmanouil Galanakis
Journal:  Pediatr Nephrol       Date:  2005-06-22       Impact factor: 3.714

3.  Study of Aetiology and Anti-biogram of Uropathogens in Children-A Retrospective Analysis.

Authors:  Dnyaneshwari Purushottam Ghadage; Swati Shivajirao Nale; Deepali Shivajirao Kamble; Vrushali Avinash Muley; Archana Bhimrao Wankhade; Rupali Jotiba Mali; Arvind Vamanrao Bhore
Journal:  J Clin Diagn Res       Date:  2014-01-12

4.  High genetic diversity of Enterococcus faecium and Enterococcus faecalis clinical isolates by pulsed-field gel electrophoresis and multilocus sequence typing from a hospital in Malaysia.

Authors:  Poh Leng Weng; Ramliza Ramli; Mariana Nor Shamsudin; Yoke-Kqueen Cheah; Rukman Awang Hamat
Journal:  Biomed Res Int       Date:  2013-05-29       Impact factor: 3.411

5.  A case of subacute infective endocarditis and blood access infection caused by Enterococcus durans.

Authors:  Tsuneaki Kenzaka; Noriko Takamura; Ayako Kumabe; Koichi Takeda
Journal:  BMC Infect Dis       Date:  2013-12-17       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.